Report stresses Chinese need for enhanced cancer drug innovation and access

A member association representing pharma companies investing in China has stressed how far they and other researchers have come in reducing cancer mortality rates, but also how far there is to go in tackling the huge burden of the disease.

The R&D Based Pharmaceutical Association Committee of the China Association of Enterprises together with Foreign Investment (RDPAC) represents 38 companies including 21 from Europe, 11 from the USA and six from Japan.

It has released a report titled Faces of Innovation: Meeting the Challenge of Cancer in Guangzhou, which outlines the cost of cancer to China and the wider world, and the potential benefits of enhancing innovation and improving drug access in extending patient life expectancy, improving quality of life and reducing the burden of disease on society.